Longeveron INC 8-K filings

Longeveron Inc. has reconstituted its Audit Committee following its annual meeting, ensuring compliance with Nasdaq listing rules.

Longeveron Inc. has revised its employment agreement with CEO Stephen Willard, adjusting salary deferral, bonus structure, severance, and equity vesting terms.

Longeveron Inc. announced special equity awards for its Executive Chairman, comprising restricted stock units and stock options, to recognize his contributions to a recent financing transaction and his continued service.

Longeveron Inc. announced that Chief Financial Officer Lisa Locklear will resign effective July 10, 2026, to pursue board opportunities, with Controller Marie Washburn expected to succeed her.

Longeveron announced that the FDA no longer considers the ELPIS II trial pivotal after determining the current primary endpoint is insufficient for efficacy.

Longeveron Inc. has repaid executive officers the difference in salary from a temporary reduction and granted restricted stock units following a recent financing transaction.

Longeveron Inc. received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement.

Longeveron Inc. has cancelled its special stockholder meeting, postponing a proposed reverse stock split vote to its next annual meeting.

Longeveron Inc. announced the initial closing of a private placement raising approximately $15.9 million, extending its cash runway into Q4 2026.

Longeveron Inc. has appointed Stephen H. Willard as its permanent Chief Executive Officer, effective February 11, 2026, alongside temporary 50% compensation reductions for top executives and employee furloughs to conserve cash.

Longeveron Inc. announced the immediate resignations of Khoso Baluch and Neha Motwani from its Board of Directors, with no stated disagreements.

Longeveron reports Q3 2025 financial results, with its pivotal HLHS trial on track for 2026 top-line data, but delays BLA submission to 2027 to extend cash runway.

Longeveron Inc. announced the appointment of Dr. George Paletta, an acclaimed surgeon, entrepreneur, and investor, to its Board of Directors, effective October 1, 2025.

Longeveron Inc. received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement for continued listing.

Longeveron Inc. has entered into an At The Market Offering Agreement to sell up to $10.7 million in Class A common stock to fund clinical development and general corporate purposes.

Longeveron Inc. announced key leadership changes, appointing Than Powell as interim CEO and Dr. Joshua Hare as Executive Chairman, following Wael Hashad's departure.

Longeveron Inc. announced its second quarter 2025 financial results and key business updates, including full enrollment in its pivotal HLHS clinical trial and FDA approval for a new pediatric cardiomyopathy IND.

Longeveron Inc. closed a public offering raising $5.0 million, with potential for an additional $12.5 million from warrant exercises, to fund its clinical development programs.

Longeveron Inc. announced that the U.S. FDA has cleared its Investigational New Drug application, allowing its lead product laromestrocel to advance directly into a Phase 2 pivotal registration clinical trial for pediatric dilated cardiomyopathy.

Longeveron Inc. announced the successful passage of all three proposals at its annual meeting of stockholders held on June 13, 2025, including the election of a Class I director, an amendment to its incentive award plan, and the ratification of its independent accounting firm.

Longeveron reports Q1 2025 financial results, highlighting progress in laromestrocel clinical trials for HLHS and Alzheimer's disease, and anticipates a BLA submission for HLHS in 2026 if ELPIS II is successful.

Longeveron Inc. has re-approved its Cash-to-Equity Program, allowing executives and directors to receive up to 80% of their cash compensation in RSUs or stock options with a premium value.

Longeveron Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs P.C. as its new auditor, effective March 13, 2025.

Longeveron reports a 237% increase in total revenue for 2024, driven by contract manufacturing and increased demand for the Bahamas Registry Trial, while advancing its Lomecel-BTM clinical programs.

Neil Hare resigns from Longeveron Inc.'s Board of Directors effective immediately due to a new professional role.

Longeveron's third quarter 2024 results show significant revenue growth and advancements in clinical trials for Lomecel-BTM.

Longeveron announced positive Phase 2a clinical trial results for Lomecel-B in Alzheimer's disease, secured key FDA designations, and raised sufficient capital to fund operations through the fourth quarter of 2025.

Longeveron Inc. has announced a $9 million registered direct offering, alongside a private placement of warrants, to fund its ongoing clinical and regulatory development.

Longeveron Inc. has been granted Fast Track designation by the FDA for its Lomecel-BTM therapy in the treatment of mild Alzheimer's disease, aiming to expedite its development and review.

Longeveron's Lomecel-BTM has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for the treatment of mild Alzheimer's disease, marking a significant milestone for the company.